Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OPN001
MIFTS: 49

Open-Angle Glaucoma

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Open-Angle Glaucoma

About this section

MalaCards integrated aliases for Open-Angle Glaucoma:

Name: Open-Angle Glaucoma 12 15 17
Glaucoma, Open-Angle 43 71
Open Angle Glaucoma 12
Pigmentary Glaucoma 12
Wide-Angle Glaucoma 12
Glaucoma Open-Angle 54
Glaucoma Simplex 12

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Eye diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1067
ICD9CM 34 365.1
MeSH 43 D005902
NCIt 49 C34641
SNOMED-CT 67 84494001
ICD10 32 H40.1
UMLS 71 C0017612
Sources

Summaries for Open-Angle Glaucoma

About this section
Disease Ontology : 12 A glaucoma characterized by optic nerve damage resulting in progressive loss of visual field and increased pressure in the eye due to trabecular blockage.

MalaCards based summary : Open-Angle Glaucoma, also known as glaucoma, open-angle, is related to glaucoma 1, open angle, a and early-onset glaucoma. An important gene associated with Open-Angle Glaucoma is MYOC (Myocilin), and among its related pathways/superpathways are Degradation of the extracellular matrix and Elastic fibre formation. The drugs Ketorolac and Trimethoprim have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and endothelial, and related phenotypes are homeostasis/metabolism and vision/eye

Sources

Related Diseases for Open-Angle Glaucoma

About this section

Diseases in the Open-Angle Glaucoma family:

Glaucoma 1, Open Angle, a Glaucoma, Primary Open Angle
Glaucoma 1, Open Angle, P Glaucoma 1, Primary Open Angle, C
Glaucoma 1, Open Angle, D Glaucoma 1, Open Angle, F
Glaucoma 1, Open Angle, B Glaucoma 1, Open Angle, J
Glaucoma 1, Open Angle, K Glaucoma 1, Open Angle, I
Glaucoma 1, Open Angle, G Glaucoma 1, Open Angle, M
Glaucoma 1, Open Angle, N Glaucoma 1, Open Angle, H
Glaucoma 1, Open Angle, O

Diseases related to Open-Angle Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 358)
# Related Disease Score Top Affiliating Genes
1 glaucoma 1, open angle, a 34.8 OPTN MYOC CYP1B1
2 early-onset glaucoma 33.9 MYOC CYP1B1
3 exfoliation syndrome 33.2 MMP1 LOXL1 GSTM1 ELN
4 juvenile glaucoma 32.7 WDR36 OPTN MYOC LTBP2 LOXL1 CYP1B1
5 glaucoma, primary open angle 32.3 WDR36 TMCO1 TGFB2 TBK1 SIX6 OPTN
6 primary angle-closure glaucoma 32.1 OPTN MYOC CYP1B1
7 ocular hypertension 32.1 WDR36 TMCO1 TGFB2 OPTN MYOC CRYAA
8 axenfeld-rieger syndrome 32.0 WDR36 MYOC LTBP2 LMX1B CYP1B1 CRYAA
9 intraocular pressure quantitative trait locus 31.9 WDR36 TMCO1 TGFB2 OPTN OPA1 MYOC
10 glaucoma, normal tension 31.6 WDR36 TMCO1 TBK1 SIX6 OPTN OPTC
11 chronic closed-angle glaucoma 31.5 TGFB2 MYOC LOXL1
12 cataract 31.4 TGFB2 SIX6 LOXL1 GSTM1 CRYAA
13 glaucoma 3, primary congenital, a 31.3 WDR36 OPTN MYOC LTBP2 CYP1B1
14 refractive error 31.3 SIX6 MMP1 CRYAA
15 optic nerve disease 31.3 WDR36 OPTN OPA1 MYOC ELN CRYAA
16 myopia 31.3 WDR36 TGFB2 SIX6 OPTC MYOC LTBP2
17 corneal edema 31.2 MYOC MMP1 LTBP2 CYP1B1
18 megalocornea 31.1 MYOC LTBP2 CYP1B1
19 traumatic glaucoma 30.9 MYOC LTBP2 CYP1B1
20 glaucoma 3, primary infantile, b 30.9 LTBP2 CYP1B1
21 eye disease 30.9 TGFB2 OPTN MYOC MMP1 LOXL1 CYP1B1
22 steroid-induced glaucoma 30.8 WDR36 TGFB2 OPTN MYOC CRYAA
23 optic nerve hypoplasia, bilateral 30.8 TMCO1 SIX6 MYOC
24 acute closed-angle glaucoma 30.8 OPTN MYOC
25 glaucoma-related pigment dispersion syndrome 30.7 WDR36 TMCO1 OPTN MYOC LOXL1 LMX1B
26 primary congenital glaucoma 30.6 WDR36 OPTN MYOC LTBP2 LOXL1 LMX1B
27 leber optic atrophy 30.6 WDR36 OPA1 MYOC CRYAA
28 lens subluxation 30.6 LTBP2 LOXL1 CRYAA
29 keratitis, hereditary 30.5 MYOC LMX1B CYP1B1 CRYAA
30 macular degeneration, age-related, 1 30.3 TGFB2 OPTC MYOC ELN CRYAA
31 macular holes 30.3 TGFB2 OPTC CRYAA
32 anterior segment dysgenesis 30.3 MYOC CYP1B1 CRYAA
33 retinal disease 30.2 OPTN OPTC MYOC CRYAA
34 marfan syndrome 30.0 TGFB2 MMP1 LTBP2 LOXL1 ELN
35 iris disease 29.6 WDR36 MYOC LTBP2 LOXL1 ELN CYP1B1
36 fundus dystrophy 29.3 SIX6 OPA1 MYOC ELN CRYAA
37 residual stage of open angle glaucoma 12.7
38 glaucoma 1, open angle, p 12.5
39 glaucoma 1, open angle, f 12.5
40 glaucoma 1, open angle, g 12.4
41 glaucoma 1, open angle, o 12.4
42 glaucoma 1, primary open angle, c 12.1
43 phacolytic glaucoma 11.5
44 yemenite deaf-blind hypopigmentation syndrome 11.2
45 joint laxity, short stature, and myopia 11.1
46 neuropathy 10.7
47 scotoma 10.7
48 uveitis 10.6
49 retinal vascular disease 10.6
50 hypothyroidism 10.6

Comorbidity relations with Open-Angle Glaucoma via Phenotypic Disease Network (PDN):


Anatomical Narrow Angle Borderline Glaucoma Glaucoma, Primary Open Angle
Hypertension, Essential Ocular Hypotension

Graphical network of the top 20 diseases related to Open-Angle Glaucoma:



Diseases related to Open-Angle Glaucoma
Sources

Symptoms & Phenotypes for Open-Angle Glaucoma

About this section

MGI Mouse Phenotypes related to Open-Angle Glaucoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.73 CAV2 CYP1B1 LMX1B LOXL1 MMP1 NTF4
2 vision/eye MP:0005391 9.28 CYP1B1 LMX1B LOXL1 LTBP2 MYOC OPA1
Sources

Drugs & Therapeutics for Open-Angle Glaucoma

About this section

Drugs for Open-Angle Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
2
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
3
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
4
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
5
Dipivefrin Approved Phase 4 52365-63-6 3105
6
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
7
Sorbitol Approved Phase 4 50-70-4 5780
8
Apraclonidine Approved Phase 4 66711-21-5 2216
9
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
10
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
11
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
12
Fluorouracil Approved Phase 4 51-21-8 3385
13
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
16
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
17
tannic acid Approved Phase 4 1401-55-4
18
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
19
Brinzolamide Approved Phase 4 138890-62-7 68844
20
Bevacizumab Approved, Investigational Phase 4 216974-75-3
21
Choline Approved, Nutraceutical Phase 4 62-49-7 305
22
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
23 Ketorolac Tromethamine Phase 4
24 Polymyxins Phase 4
25 Brimonidine Tartrate Phase 4 70359-46-5
26 Lubricant Eye Drops Phase 4
27 Brimonidine Tartrate, Timolol Maleate Drug Combination Phase 4
28 Anti-Infective Agents, Local Phase 4
29 Benzalkonium Compounds Phase 4
30 Anti-Asthmatic Agents Phase 4
31 Dermatologic Agents Phase 4
32 Anti-Allergic Agents Phase 4
33 Bronchodilator Agents Phase 4
34 Dextrans Phase 4
35 Plasma Substitutes Phase 4
36 Anticoagulants Phase 4
37 Blood Substitutes Phase 4
38 Immunosuppressive Agents Phase 4
39 Antimetabolites Phase 4
40 Ophthalmic Solutions Phase 4
41 Anesthetics Phase 4
42 cefuroxime axetil Phase 4
43 Pharmaceutical Solutions Phase 4
44 Carbonic Anhydrase Inhibitors Phase 4
45 Angiogenesis Inhibitors Phase 4
46 Mitomycins Phase 4
47 Alkylating Agents Phase 4
48 Anti-Bacterial Agents Phase 4
49 Antibiotics, Antitubercular Phase 4
50 Mitogens Phase 4

Interventional clinical trials:

(show top 50) (show all 824)
# Name Status NCT ID Phase Drugs
1 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent Unknown status NCT01252914 Phase 4
2 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Stents Unknown status NCT00326079 Phase 4
3 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% Unknown status NCT01444040 Phase 4 Travoprost
4 Semi-Automated Patterned Laser Trabeculoplasty Unknown status NCT00804323 Phase 4
5 A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) Unknown status NCT02868190 Phase 4
6 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin Unknown status NCT02873806 Phase 4 Topical travoprost;Tobramycin;Dexamethasone
7 Phase 4 Study to Evaluate Efficacy And Safety of Three Different Preparations of Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
8 An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma Unknown status NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
9 Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
10 The Impact of Topical Prostaglandin Analogs on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4 topical prostaglandin analogs
11 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
12 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
13 A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma Unknown status NCT02231515 Phase 4
14 A Randomised Controlled Trial to Compare the Clinical Effectiveness of Selective Laser Trabeculoplasty (SLT) Versus Topical Therapy in the Treatment of Pseudoexfoliative Glaucoma Unknown status NCT01704989 Phase 4 Prostagladin
15 A Pilot Study on the Effects of Cosopt on IOP Lowering and Ocular Diastolic Perfusion Pressure in Patients Not Controlled With Xalatan Monotherapy Unknown status NCT00796198 Phase 4 Xalatan+Cosopt;Xalatan
16 New Horizons in the Treatment of Vitreous Floaters: Efficacy and Safety of Vitreolysis With the Ultra Q Reflex YAG Laser (Ellex) Unknown status NCT02812004 Phase 4
17 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents Completed NCT01252888 Phase 4
18 A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects. Completed NCT00326040 Phase 4
19 A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects. Completed NCT00326014 Phase 4
20 Latanoprost Versus Fotil Completed NCT00304785 Phase 4 latanoprost 0.005%;Fotil;placebo
21 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02020512 Phase 4 0.03% Bimatoprost
22 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02003534 Phase 4 0.15% Brimonidine Tartrate
23 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4 Bimatoprost 0.03%
24 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
25 A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents Completed NCT01252862 Phase 4
26 DuoTrav® Eye Drops As Replacement Therapy Program Completed NCT00828906 Phase 4 DuoTrav
27 Lumigan Versus Cosopt Completed NCT00273455 Phase 4 bimatoprost 0.03%;dorzolamide 2%/timolol maleate 0.5% fixed combination;placebo
28 Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy Completed NCT01510145 Phase 4 Travoprost 0.004% BAK-free
29 Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
30 Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-Line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg Completed NCT00647101 Phase 4 Latanoprost
31 Patient Satisfaction With Timolol Maleate in Sorbate, Generic Timolol Gel Forming Solution or Timolol Hemihydrate in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
32 Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
33 ELAZOP Switching Study in Korea Completed NCT01055366 Phase 4 Elazop (Azarga)
34 Assessing the Safety and Efficacy of Switching to AZARGA® (Brinzolamide/Timolol Fixed Combination) as Replacement Therapy in Patients With Uncontrolled Intraocular Pressure in Taiwan Completed NCT01484951 Phase 4 Brinzolamide 1% and timolol 0.5% fixed combination eye drops
35 Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker Completed NCT02003391 Phase 4 Beta-blocker monotherapy;Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
36 Assessing the Efficacy and Tolerability of Changing to DUOTRAV® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed) Completed NCT01327599 Phase 4 Travoprost 0.004%+Timolol 0.5% ophthalmic solution
37 A Prospective, Unmasked, Randomized Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-Angle Glaucoma Completed NCT00913029 Phase 4 latanoprost/timolol
38 A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma Completed NCT00911924 Phase 4
39 Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
40 Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN® Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
41 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
42 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004% Completed NCT01443988 Phase 4 Travoprost
43 Cosopt Versus Xalatan Completed NCT00273429 Phase 4 timolol maleate 0.5%;dorzolamide/timolol maleate fixed combination;latanoprost 0.005%;placebo
44 24-hour IOP-lowering Effect of Brimonidine 0.1% Completed NCT00457795 Phase 4 brimonidine 0.1% (Alphagan® P)
45 Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
46 Post Market Multicentric Evaluation of the AqueSys XEN Implant in Moderate Primary Open Angle Glaucoma Subjects Completed NCT02006693 Phase 4
47 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
48 The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
49 Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01340014 Phase 4 Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension;Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution
50 A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate

Search NIH Clinical Center for Open-Angle Glaucoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Betaxolol
Betaxolol Hydrochloride
bimatoprost
brimonidine
Brimonidine tartrate
brinzolamide
Carteolol
Carteolol Hydrochloride
Dipivefrin
Dipivefrin hydrochloride
dorzolamide
Dorzolamide hydrochloride
Echothiophate Iodide
Epinephrine
epinephrine bitartrate
epinephrine hydrochloride
epinephryl borate
isopropyl unoprostone
latanoprost
Levobunolol
Levobunolol Hydrochloride
Methazolamide
Metipranolol
Metipranolol hydrochloride
Phenylephrine
Phenylephrine bitartrate
Phenylephrine Hydrochloride
Phenylephrine Tannate
Racepinephrine Hydrochloride
Timolol
Timolol Hemihydrate
Timolol Maleate
travoprost
UNOPROSTONE

Cochrane evidence based reviews: glaucoma, open-angle

Sources

Genetic Tests for Open-Angle Glaucoma

About this section
Sources

Anatomical Context for Open-Angle Glaucoma

About this section

MalaCards organs/tissues related to Open-Angle Glaucoma:

40
Eye, Testes, Endothelial, Retina, Brain, Cortex, Skin
Sources

Publications for Open-Angle Glaucoma

About this section

Articles related to Open-Angle Glaucoma:

(show top 50) (show all 11757)
# Title Authors PMID Year
1
Little evidence for association of the glaucoma gene MYOC with open-angle glaucoma. 61 54
20447966 2010
2
Mutations of optineurin in amyotrophic lateral sclerosis. 54 61
20428114 2010
3
Major LOXL1 risk allele is reversed in exfoliation glaucoma in a black South African population. 54 61
20431720 2010
4
Adenoviral gene transfer of active human transforming growth factor-{beta}2 elevates intraocular pressure and reduces outflow facility in rodent eyes. 61 54
19959644 2010
5
New mutation in the MYOC gene and its association with primary open-angle glaucoma in a Chinese family. 61 54
19688280 2010
6
Functional analysis of CYP1B1 mutations and association of heterozygous hypomorphic alleles with primary open-angle glaucoma. 54 61
19793111 2010
7
Mutation spectrum of the CYP1B1 gene for congenital glaucoma in the Japanese population. 61 54
20151268 2010
8
Myocilin in the trabecular meshwork of eyes with primary open-angle glaucoma. 61 54
19662433 2009
9
Correction of the disease phenotype of myocilin-causing glaucoma by a natural osmolyte. 54 61
19234343 2009
10
A novel optineurin genetic mutation associated with open-angle glaucoma in a Chinese family. 61 54
19710941 2009
11
Genetic risk for primary open-angle glaucoma determined by LMX1B haplotypes. 61 54
18952915 2009
12
Glaucoma-associated myocilin: a better understanding but much more to learn. 54 61
18804106 2009
13
Lack of association between optineurin gene variants T34T, E50K, M98K, 691_692insAG and R545Q and primary open angle glaucoma in Brazilian patients. 61 54
19172505 2009
14
Multiple gene polymorphisms analysis revealed a different profile of genetic polymorphisms of primary open-angle glaucoma in northern Chinese. 61 54
19145250 2009
15
Different WDR36 mutation pattern in Chinese patients with primary open-angle glaucoma. 61 54
19347049 2009
16
Optineurin and its mutants: molecules associated with some forms of glaucoma. 54 61
19672125 2009
17
[Matrix metalloproteinases (MMPs): modern molecular markers of open-angle glaucoma diagnosis and therapy]. 61 54
19002081 2008
18
Two novel myocilin mutations in a Chinese family with primary open-angle glaucoma. 54 61
18776955 2008
19
Elevated amounts of myocilin in the aqueous humor of transgenic mice cause significant changes in ocular gene expression. 54 61
18602390 2008
20
Lack of association between LOXL1 variants and primary open-angle glaucoma in three different populations. 61 54
18421074 2008
21
Lysyl oxidase-like 1 gene polymorphisms in Japanese patients with primary open angle glaucoma and exfoliation syndrome. 61 54
18636115 2008
22
Seed-based systematic discovery of specific transcription factor target genes. 54 61
18485006 2008
23
Leu432Val polymorphism in CYP1B1 as a susceptible factor towards predisposition to primary open-angle glaucoma. 54 61
18483560 2008
24
Gene expression profiles of human trabecular meshwork cells induced by triamcinolone and dexamethasone. 61 54
18436822 2008
25
Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma. 54 61
18436825 2008
26
Presence of myocilin sequence variants in Japanese patients with open-angle glaucoma. 61 54
18334962 2008
27
Glutathione S-transferase M1 and T1 polymorphisms in Arab glaucoma patients. 54 61
18334963 2008
28
Absence of optineurin (OPTN) gene mutations in Taiwanese patients with juvenile-onset open-angle glaucoma. 61 54
18385781 2008
29
Myocilin allele-specific glaucoma phenotype database. 61 54
17966125 2008
30
Optineurin coding variants in Ghanaian patients with primary open-angle glaucoma. 54 61
19096531 2008
31
Evaluation of LOXL1 polymorphisms in primary open-angle glaucoma in southern and northern Chinese. 61 54
19098994 2008
32
Effects of timolol on MYOC, OPTN, and WDR36 RNA levels. 54 61
18195223 2008
33
Clinical and genetic characteristics of primary juvenile-onset open-angle glaucoma (JOAG). 54 61
18214788 2008
34
LOXL1 variants in elderly Japanese patients with exfoliation syndrome/glaucoma, primary open-angle glaucoma, normal tension glaucoma, and cataract. 54 61
18958304 2008
35
Suppression of keratoepithelin and myocilin by small interfering RNAs (siRNA) in vitro. 61 54
18079684 2007
36
What increases outflow resistance in primary open-angle glaucoma? 61 54
17998032 2007
37
Association between primary open-angle glaucoma and WDR36 DNA sequence variants in Japanese. 54 61
17960130 2007
38
Identification of mutations in the myocilin (MYOC) gene in Taiwanese patients with juvenile-onset open-angle glaucoma. 54 61
17893664 2007
39
MYOC gene mutations in Spanish patients with autosomal dominant primary open-angle glaucoma: a founder effect in southeast Spain. 61 54
17893668 2007
40
Population differences in elastin maturation in optic nerve head tissue and astrocytes. 54 61
17591890 2007
41
[Investigation on the mutation of MYOC gene in two family pedigrees with primary open-angle glaucoma in Shanxi]. 54 61
17867509 2007
42
Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma. 54 61
17615537 2007
43
Myocilin variants in Indian patients with open-angle glaucoma. 54 61
17562996 2007
44
Role of CYP1B1, MYOC, OPTN, and OPTC genes in adult-onset primary open-angle glaucoma: predominance of CYP1B1 mutations in Indian patients. 61 54
17563717 2007
45
Evaluation of the OPTC gene in primary open angle glaucoma: functional significance of a silent change. 61 54
17359525 2007
46
Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells. 61 54
17251470 2007
47
Suppression of keratoepithelin and myocilin by small interfering RNA (an American Ophthalmological Society thesis). 54 61
18427622 2007
48
Aggregated myocilin induces russell bodies and causes apoptosis: implications for the pathogenesis of myocilin-caused primary open-angle glaucoma. 54 61
17200186 2007
49
The OPA1 gene polymorphism is associated with normal tension and high tension glaucoma. 61 54
17188046 2007
50
SNPs and interaction analyses of noelin 2, myocilin, and optineurin genes in Japanese patients with open-angle glaucoma. 54 61
17122126 2006
Sources

Variations for Open-Angle Glaucoma

About this section
Sources

Expression for Open-Angle Glaucoma

About this section
Search GEO for disease gene expression data for Open-Angle Glaucoma.
Sources

Pathways for Open-Angle Glaucoma

About this section

Pathways related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Degradation of the extracellular matrix 65
Show member pathways
 12.09 TGFB2 OPTC MMP1 LTBP2 LOXL1 ELN
2
Elastic fibre formation 65
Show member pathways
 10.79 TGFB2 LTBP2 LOXL1 ELN
Sources

GO Terms for Open-Angle Glaucoma

About this section

Cellular components related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.35 TGFB2 MYOC LTBP2 LOXL1 ELN
2 extracellular matrix GO:0031012 9.02 OPTC MMP1 LTBP2 LOXL1 ELN

Biological processes related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.35 WDR36 SIX6 OPA1 CYP1B1 CRYAA
2 positive regulation of xenophagy GO:1904417 9.16 TBK1 OPTN
3 collagen fibril organization GO:0030199 8.92 TGFB2 OPTC LOXL1 CYP1B1
Sources

Sources for Open-Angle Glaucoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....